Definium Therapeutics, formerly known as MindMed, unveiled its new brand, emphasizing its commitment to psychiatric transformation and innovative therapies.
The company is on track to deliver three Phase 3 readouts in 2026 for DT120 Orally Disintegrating Tablet in GAD and MDD.
Definium Therapeutics aims to provide long-term remission for patients with psychiatric and neurological disorders through its cutting-edge therapeutics.
Rebranding
MindMed rebrands to Definium Therapeutics, reflecting the company's focus on scientific leadership and psychiatric innovation.
Phase 3 Readouts
Three Phase 3 readouts expected in 2026 for DT120 ODT in GAD and MDD, marking significant milestones for the company.
Nasdaq Ticker Symbol
Trading under the new ticker symbol 'DFTX' on Nasdaq effective January 13, 2026, to align with the rebranding.
Ambitious Mission
Definium Therapeutics aims to unlock healing at scale by applying scientific rigor to psychedelics and advancing care for patients with innovative therapies.
- Definium Therapeutics is positioned as a leader in psychiatric drug development, with a focus on solving the root causes of mental health disorders.
- The company's rebranding to Definium signifies a strategic shift toward offering accessible treatments and driving long-term value for shareholders.
With a clear vision and disciplined execution, Definium Therapeutics is poised to revolutionize psychiatric care and set new standards in the industry.